Targeting the untargetable KRAS in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS is a well-known proto-oncogene family implicated in cancer development.
• Gain-of-function mutations in RAS occur in approximately 30% of human cancers.
• KRAS is the most frequently mutated RAS isoform, driving significant research efforts.

Purpose of the Study:

• To review recent progress in developing KRAS-targeted anticancer strategies.
• To highlight novel approaches for inhibiting KRAS activation.
• To provide insights for future therapeutic development in KRAS-mutant cancers.

Main Methods:

• Literature review of recent studies on KRAS inhibitors.
• Analysis of direct KRAS inhibition strategies.
• Evaluation of indirect approaches targeting KRAS activation pathways.

Main Results:

• Despite decades of research, KRAS has been considered 'undruggable'.
• Recent studies show renewed interest and progress in developing KRAS inhibitors.
• Strategies include direct targeting of mutant KRAS and inhibition of its activation steps.

Conclusions:

• Targeting KRAS remains a significant challenge in oncology.
• Emerging strategies offer promising avenues for treating KRAS-mutant cancers.
• Continued research is crucial for translating these findings into effective therapies.